CytomX Therapeutics Inc. (CTMX)
NASDAQ: CTMX
· Real-Time Price · USD
2.90
0.06 (2.11%)
At close: Sep 26, 2025, 3:59 PM
2.94
1.33%
After-hours: Sep 26, 2025, 07:57 PM EDT
CytomX Therapeutics Revenue Breakdown
| Period Ending | Mar 31, 2025 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|
| E G F R Products Revenue | 8.4M | 42.3M | 43.7M |
| E G F R Products Revenue Growth | -80.14% | -3.20% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 6.62M | 9.43M | 5.62M | 7.95M | 8.39M | 7.75M | 7.83M | 6.81M | 7.4M | 7.98M | 10.07M | 10.49M | 11.75M | 10.54M | 9.46M | 11.09M | 9.39M | 9.23M | 9.14M | 8.63M | 8.68M | 9.57M | 9.22M | 8.46M | 9.41M | 9.67M | 8.97M | 8.14M | 9.04M | 7.36M | 7.62M | 6.25M | 6.05M | 5.69M | 5.15M | 5.03M | 4.65M | 5.04M | 4.01M | 4.05M | 2.55M | 1.95M |
| Selling, General, and Administrative Revenue Growth | -29.76% | +67.64% | -29.28% | -5.27% | +8.27% | -0.93% | +14.88% | -7.94% | -7.22% | -20.76% | -4.03% | -10.71% | +11.43% | +11.50% | -14.70% | +18.01% | +1.80% | +0.90% | +5.92% | -0.53% | -9.32% | +3.85% | +8.91% | -10.07% | -2.72% | +7.79% | +10.30% | -10.01% | +22.92% | -3.41% | +21.88% | +3.31% | +6.29% | +10.42% | +2.40% | +8.31% | -7.80% | +25.72% | -1.04% | +58.74% | +31.14% | n/a |
| Research and Development Revenue | 13.32M | 18.87M | 14.79M | 21.37M | 25.17M | 22.05M | 18.94M | 16.45M | 20.67M | 21.18M | 19.56M | 30.37M | 31.16M | 30.56M | 36.58M | 29.14M | 26.1M | 22.37M | 22.01M | 24.05M | 24.07M | 42.81M | 36.44M | 27.97M | 30.84M | 36.38M | 28.31M | 27.55M | 25.55M | 22.46M | 20.7M | 28.92M | 28.08M | 14.58M | 15.35M | 13.34M | 12.71M | 13.37M | 9.5M | 9.16M | 5.03M | 4.66M |
| Research and Development Revenue Growth | -29.39% | +27.57% | -30.78% | -15.11% | +14.15% | +16.45% | +15.13% | -20.43% | -2.38% | +8.23% | -35.57% | -2.54% | +1.96% | -16.46% | +25.52% | +11.66% | +16.67% | +1.65% | -8.49% | -0.07% | -43.79% | +17.49% | +30.30% | -9.30% | -15.23% | +28.51% | +2.75% | +7.81% | +13.78% | +8.47% | -28.41% | +3.01% | +92.62% | -5.03% | +15.08% | +4.97% | -4.94% | +40.64% | +3.78% | +81.94% | +7.91% | n/a |